Key clinical point: Janus Kinase (JAK) inhibitors demonstrated promising efficacy in reducing disease severity in patients with psoriatic arthritis (PsA).
Major finding: Treatment with JAK inhibitors vs. placebo was associated with higher odds of achieving ≥20% improvement in American College of Rheumatology (ACR) score (odds ratio [OR], 4.45; 95% CI, 3.64-5.44), with similar outcomes observed with tofacitinib vs. placebo (OR, 2.96; 95% CI, 2.01-4.35) and non-tofacitinib JAK inhibitors vs. placebo (OR, 5.41; 95% CI, 3.95-7.40).
Study details: Findings are from a meta-analysis of 15 randomized controlled trials including 6,757 patients with moderate-to-severe plaque psoriasis or PsA who received treatment with a JAK inhibitor or placebo.
Disclosures: S Sarabia declared receiving summer student grant from the Queen’s University Faculty of Medicine. The authors declared no conflicts of interest.
Source: Sarabia S et al. Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: A systematic review and meta-analysis. BMC Rheumatol. 2022;6(1):71 (Sep 27). Doi: 10.1186/s41927-022-00287-7.